# US 2022/0275461 A1 · Diagnostics and methods for prognosing response to immunotherapy based on the methylation status of immune synapse gene signature

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0275461 A1
- Document ID: US20220275461A1
- Status: Published application
- Kind: A1
- Application number: 17/636,532
- Filed: 2020-08-21
- Published: 2022-09-01
- Earliest claimed: 2019-08-21
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: Sungjune KIM; Anders BERGLUND
- Web page: https://patentgrep.com/patent/US20220275461A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods for using the methylation status of a cancerous tissue to assess the susceptibility of a cancer to immunotherapy and determine new treatment regimens. Disclosed are methods related to producing an immunotherapeutic regimen based on the amount of methylation in co-stimulatory genes and/or immune checkpoint genes, as well as, methods of treating an immunogenic cancer based on the same.

## Claims

### Claim 1

A method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis in a subject comprising:
a. obtaining a tissue sample from the subject;
b. assaying the amount of methylation of one or more co-stimulatory genes and/or one or more immune checkpoint genes in the tissue sample; and
c. administering to the subject an immunotherapy wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue is detected and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue is detected.

### Claim 2 (depends on 1)

The method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis claim 1, wherein the one or more co-stimulatory gene comprises cluster of differentiation (CD) 40 (CD40), CD70, homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes (LIGHT), OX40L, CD137L (4-1BBL), glucocorticoid-induced tumour-necrosis-factor-receptor-related protein (GITR) ligand (GITRL), B7 related protein 1 (B7RP1), and/or human leukocyte antigen (HLA)-A (HLA-A).

### Claim 3 (depends on 1)

The method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis claim 1, wherein the one or more immune checkpoint gene comprises carcinoembryonic antigen-related adhesion molecule (CEACAM) 1 (CEACAM1), Galectin 9, programmed death ligand (PDL) 1 (PDL1), PDL2, V-domain Ig suppressor of T cell activation (VISTA), B7-H3, B7-H4, B7-2 (CD86), B7-1 (CD80), HHLA2, CD155, and/or Galectin 3.

### Claim 4 (depends on 1)

The method treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 1, wherein the immunotherapy comprises an antibody, cytokine, natural killer (NK) cell, chimeric antigen receptor (CAR) T cell, CAR NK cell, tumor infiltrating lymphocyte (TIL), marrow infiltrating lymphocyte (MIL), and/or tumor infiltrating NK cell (TINK).

### Claim 5 (depends on 1)

The method treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 1, wherein the antibody comprises an immune checkpoint inhibitor blockade.

### Claim 6 (depends on 1)

The method treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 1, further comprising administering to the subject an inhibitor of methylation when the amount of methylation of the one or more co-stimulatory genes is increased relative to a control.

### Claim 7 (depends on 6)

The method treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 6, wherein the inhibitor of methylation comprises azacytidine, decitabine, and/or zebularine.

### Claim 8 (depends on 1)

The method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 1, wherein the cancer comprises adenocarcinoma, breast cancer, bladder cancer, cervical cancer, colon cancer, lymphoma, esophageal cancer, renal cancer, lung cancer, mesothelioma, head and neck cancer, cholangiocarcinoma, liver cancer, ovarian cancer, pancreatic cancer, prostate cancer, adrenal gland cancer, nerve cell cancer, rectal cancer, melanoma, sarcoma, testicular cancer, thyroid cancer, uterine cancer, or ocular cancer.

### Claim 9 (depends on 8)

The method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 8, wherein the cancer comprises adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectum adenocarcinoma, sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ sell tumors, thyroid carcinoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, or uveal melanoma.

### Claim 10 (depends on 1)

The method of treating, inhibiting, reducing, ameliorating, and/or preventing an immunogenic cancer or metastasis of claim 1, wherein methylation is measured by performing principal component (PC) analysis (PCA) of the one or more co-stimulatory genes and/or one or more immune checkpoint genes; wherein PChigh indicates an increase in methylation and PClow indicates a decrease in methylation.

### Claim 11

A method of assessing the suitability of an immunotherapy treatment regimen for the treatment an immunogenic cancer or metastasis in a subject comprising:
a. obtaining a tissue sample from the subject; and
b. assaying the amount of methylation of one or more co-stimulatory genes and/or one or more immune checkpoint genes in the tissue sample;
wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that immunotherapy is suitable for treatment of the cancer in the subject.

### Claim 12 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the one or more co-stimulatory gene comprises cluster of differentiation (CD) 40 (CD40), CD70, homologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes (LIGHT), OX40L, CD137L (4-1BBL), glucocorticoid-induced tumour-necrosis-factor-receptor-related protein (GITR) ligand (GITRL), B7 related protein 1 (B7RP1), and/or human leukocyte antigen (HLA)-A (HLA-A)

### Claim 13 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the one or more immune checkpoint gene comprises carcinoembryonic antigen-related adhesion molecule (CEACAM) 1 (CEACAM1), Galectin 9, programmed death ligand (PDL) 1 (PDL1), PDL2, V-domain Ig suppressor of T cell activation (VISTA), B7-H3, B7-H4, B7-2 (CD86), B7-1 (CD80), HHLA2, CD155, and/or Galectin 3.

### Claim 14 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the immunotherapy comprises an antibody, cytokine, natural killer (NK) cell, chimeric antigen receptor (CAR) T cell, CAR NK cell, tumor infiltrating lymphocyte (TIL), marrow infiltrating lymphocyte (MIL), and/or tumor infiltrating NK cell (TINK).

### Claim 15 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the antibody comprises an immune checkpoint inhibitor blockade.

### Claim 16 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein a decrease in the methylation of one or more co-stimulatory genes relative to a normal control tissue or an increase in the methylation of one or more immune checkpoint genes relative to a normal control indicates that an inhibitor of methylation should not be administered to the subject.

### Claim 17 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue indicates that an inhibitor of methylation can be administered to the subject.

### Claim 18 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the cancer comprises adenocarcinoma, breast cancer, bladder cancer, cervical cancer, colon cancer, lymphoma, esophageal cancer, renal cancer, lung cancer, mesothelioma, head and neck cancer, cholangiocarcinoma, liver cancer, ovarian cancer, pancreatic cancer, prostate cancer, adrenal gland cancer, nerve cell cancer, rectal cancer, melanoma, sarcoma, testicular cancer, thyroid cancer, uterine cancer, or ocular cancer.

### Claim 19 (depends on 18)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 18, wherein the cancer comprises adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectum adenocarcinoma, sarcoma, skin cutaneous melanoma, stomach adenocarcinoma, testicular germ sell tumors, thyroid carcinoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma, or uveal melanoma

### Claim 20 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the assessment is conducted prior to the commencement of any immunotherapy regimen; wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that the subject can start an immunotherapy regimen; and wherein a decrease in the methylation or same amount of methylation of one or more co-stimulatory genes relative to a normal control tissue and/or an increase in the methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that the subject should start an anti-cancer regimen that is not an immunotherapy.

### Claim 21 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein the assessment is conducted after to the commencement of an immunotherapy regimen; wherein an increase in the methylation of one or more co-stimulatory genes relative to a normal control tissue and/or a decrease in the methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that the subject can continue an immunotherapy regimen; and wherein a decrease or same amount of methylation of one or more co-stimulatory genes relative to a normal control tissue and/or an increase or same amount of methylation of one or more immune checkpoint genes relative to a normal control tissue indicates that the subject should discontinue an anti-cancer regimen that is not an immunotherapy.

### Claim 22 (depends on 11)

The method of assessing the suitability of an immunotherapy treatment regimen for the treatment of an immunogenic cancer or metastasis in a subject of claim 11, wherein methylation is measured by performing principal component analysis of the one or more co-stimulatory genes and/or one or more immune checkpoint genes; wherein PChigh indicates an increase in methylation and PClow indicates a decrease in methylation.
